8-K: Propanc Biopharma Secures $55,000 Convertible Note and Additional Financing for Working Capital

Propanc Biopharma, Inc. has entered into a securities purchase agreement for a $55,000 convertible note and other financing arrangements to bolster its working capital.

Summary

• Propanc Biopharma, Inc. entered into a securities purchase agreement effective April 15, 2025, with GS Capital Partners, LLC for a convertible promissory note with a principal amount of $55,000.
• The purchase price for the note was $50,000, reflecting a $5,000 original issue discount.
• The company intends to use the net proceeds for general working capital purposes.
• The note matures on December 15, 2025, and bears interest at 8% per annum, potentially increasing to 24% upon an Event of Default.
• The holder has the option to convert the note into common stock at a fixed price of $5.00 per share, which may decrease to $2.50 if the stock trades below $4.00 for more than five consecutive trading days.
• In the event of default, the conversion price will be the lowest trading price in the prior ten days.
• The company also entered into a loan agreement effective April 13, 2025, with a Board Member for $63,188 AUD, bearing interest at 12% per annum, maturing on June 30, 2025.
• Additionally, Propanc Biopharma entered into a securities purchase agreement on March 31, 2025, with another investor for a convertible promissory note with a principal amount of $79,200, purchased for $67,000.
• This note matures on January 30, 2026, and has a one-time interest charge of 15%, with repayment in five installments.
• The investor has the option to convert the note after an Event of Default at a conversion price of 65% of the lowest trading price in the ten days prior to conversion.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company is securing funding, it comes with the risks associated with debt and potential dilution. The terms of the financing are fairly standard for a company of this size and stage.

Positives

• The financing provides Propanc Biopharma with additional working capital.
• The convertible notes offer flexibility in managing debt and potential equity dilution.
• The loan from a Board Member demonstrates internal confidence in the company.

Negatives

• The convertible notes include potentially dilutive conversion features.
• The notes contain events of default that could accelerate repayment obligations.
• The company is incurring additional debt and interest expenses.

Risks

• Failure to meet financial obligations could trigger events of default.
• Dilution of existing shareholders' equity could occur upon conversion of the notes.
• Market volatility could impact the conversion price and the company's ability to manage its capital structure.

Future Outlook

The company intends to use the net proceeds from these financing activities for general working capital purposes.

Industry Context

Small biopharma companies often rely on convertible notes and loans to fund operations, especially during early stages of development. These financing methods can be attractive to investors seeking potential equity upside while providing the company with necessary capital.

Comparison to Industry Standards

• Convertible notes are a common financing tool for small-cap and micro-cap companies, particularly in the biotech and pharmaceutical sectors.
• The interest rates and conversion terms are within the typical range for such financings, but the specifics depend heavily on the company's risk profile and stage of development.
• Comparable companies might include other early-stage biopharma firms listed on the OTC Markets or smaller exchanges that have also utilized convertible debt to fund research and development or general operations.
• For example, companies like Aeterna Zentaris or Diffusion Pharmaceuticals have used similar financing strategies in the past.

Related Party Transactions

• The company entered into a loan agreement with one of its Board of Directors.

Stakeholder Impact

• Shareholders may experience dilution if the convertible notes are converted into common stock.
• The financing provides the company with resources to continue operations, which benefits employees.
• The company's ability to meet its obligations to creditors is dependent on its financial performance.

Next Steps

• The company will use the proceeds for general working capital.
• The company needs to manage its debt obligations and potential equity dilution.
• The company must comply with the terms and conditions of the agreements to avoid events of default.

Key Dates

Keywords

convertible note, securities purchase agreement, working capital, financing, common stock, loan agreement, Propanc Biopharma